Quince Therapeutics (QNCX) Stock Analysis

What Quince Therapeutics does

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

Key metrics

ETFs linked to QNCX

Broad-market and Healthcare sector ETFs an investor holding Quince Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how QNCX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Quince Therapeutics?

Quince Therapeutics trades under the ticker QNCX on NASDAQ.

Which exchange is QNCX listed on?

QNCX is listed on NASDAQ.

What sector does Quince Therapeutics operate in?

Quince Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze QNCX in a portfolio?

PortView shows QNCX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.